Can your genes predict which eye drug works best?

NCT ID NCT06952452

Recruiting now Knowledge-focused Sponsor: Parc de Salut Mar Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The goal is to see if certain gene variants are linked to better or worse vision outcomes, which could help personalize treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ranibizumab and bevacizumab (anti-VEGF drugs injected into the eye)
What this could lead to: If successful, this could help doctors choose the most effective anti-VEGF drug for each patient based on their genetics, potentially improving vision outcomes and reducing costs.
What could go wrong: This is a large phase 3 trial, but it focuses on genetic markers that may not strongly predict treatment response. The results may not change clinical practice if the genetic links are weak.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WET AGE RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Hospital Universitario de Canarias
RECRUITING

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Hospital de la Santa Creu i Sant Pau
RECRUITING

Barcelona, Spain
Hospital la Esperanza
RECRUITING

Barcelona, Spain
Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC La Paz)
RECRUITING

Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.